Silexion Therapeutics (NASDAQ:SLXN) Lowered to Hold Rating by Maxim Group

Silexion Therapeutics (NASDAQ:SLXN) was downgraded by investment analysts at Maxim Group from a “strong-buy” rating to a “hold” rating in a research report issued on Wednesday,Zacks.com reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Silexion Therapeutics Stock Up 15.0%

SLXN stock opened at $1.84 on Wednesday. The company’s 50-day simple moving average is $3.17 and its 200-day simple moving average is $10.12. Silexion Therapeutics has a 52-week low of $1.50 and a 52-week high of $223.60. The firm has a market cap of $772,800.00, a P/E ratio of -0.02 and a beta of -0.26.

Silexion Therapeutics (NASDAQ:SLXN) last posted its earnings results on Friday, May 15th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($12.90) by $12.05. On average, analysts anticipate that Silexion Therapeutics will post -45.5 earnings per share for the current fiscal year.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.